Business Context and Reporting Period
This Form 10-Q is a quarterly report for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.) for the period ended December 31, 2000. The company operates in two segments: analytical services (chemistry support for pharmaceutical companies) and products (scientific instruments for trace organic compound determination).
Key Financial Metrics
| Metric | Q1 2001 (Ended Dec 31, 2000) | Q1 2000 (Ended Dec 31, 1999) |
|---|---|---|
| Total Revenue | $5,426,000 | $4,446,000 |
| Gross Profit | $2,422,000 | $1,409,000 |
| Operating Income | $491,000 | ($472,000) |
| Net Income | $195,000 | ($372,000) |
| Cash and Equivalents | $391,000 | $597,000 |
| Revolving Line of Credit Outstanding | $2,496,000 | N/A |
| Long-Term Debt (Less Current) | $2,917,000 | N/A |
Margins: Gross margin improved to 44.6% from 31.7% year-over-year. The effective tax rate was 45.1% compared to 34.5% in the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22.0% to $5.4 million, driven primarily by a 39.3% increase in product revenue ($2.33M vs $1.67M) due to sales of Culex automated blood sampling devices.
- Profitability Turnaround: The company reported a net income of $195,000, reversing a net loss of $372,000 in the same period the previous year. Operating income swung from a loss of $472,000 to a profit of $491,000.
- Cost Efficiency: Cost of revenue decreased 1.1% despite revenue growth. Cost of services revenue as a percentage of revenue dropped from 87.2% to 72.4% due to increased preclinical service revenue.
- Cash Flow: Net cash used by operating activities improved significantly to a use of $64,000 from $742,000 in the prior year. However, cash and cash equivalents decreased by $86,000 during the quarter due to investing activities.
Outlook, Risks, and Contingencies
- Liquidity: Management believes cash from operations and the existing $3.5 million line of credit (with $2.5 million outstanding) are sufficient to fund working capital and capital expenditure requirements.
- Debt Obligations: The company has a working capital line expiring April 1, 2001, and a $3.5 million commercial mortgage with a balloon payment of $2.35 million due June 24, 2004.
- Legal Proceedings: A patent infringement lawsuit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes was settled during the quarter for an immaterial amount.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks to strategic plans, future profitability, and capital requirements.
Investor Verification Checklist
- Verify the sustainability of the 22% revenue growth, specifically the demand for Culex automated blood sampling devices.
- Confirm the company's ability to meet the $2.35 million balloon payment on the commercial mortgage due in 2004.
- Monitor the utilization of the $3.5 million line of credit, which expires in April 2001, and ensure compliance with financial covenants.
- Assess the impact of the 45.1% effective tax rate on future net income projections.
- Review the increase in accounts receivable ($367,000 increase) to ensure collection trends remain healthy.